4
Changes in Ownership
Xilio Therapeutics, Inc. Filed Acc 0001415889-25-000404
SVP, FINANCE AND ACCOUNTING sold 1,803 shares at $0.98 ($1,774)
- SVP, FINANCE AND ACCOUNTING acquired 5,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | 2025-01-01 | Option exercise 10b5-1 | +5,000 | 5,000 | D | ||
| Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | 2025-01-02 | Sale 10b5-1 | −1,803 | $0.98 | $1,774 | 3,197 | D |
| Derivatives | |||||||
| Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | 2025-01-01 | Option exercise · Restricted Stock Units 10b5-1 | −5,000 | 15,000 | D | ||
| Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | 2025-01-01 | Grant or award · Stock Option (right to buy) 10b5-1 | +60,000 | 60,000 | D | ||
| Open-market sales · 1,803 sh · avg $0.98 · $1,774 | |||||||
Loading xslF345X05/form4-01032025_040109.xml…